1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control